Search by Drug Name

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for AMPYRA

Clinical trials list

click for details

Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis
A Single Dose Pharmaco-Diagnostic for Peripheral Nerve Continuity After Trauma
Use of Dalfampridine in Primary Lateral Sclerosis
A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets.
Efficacy of Dalfampridine on Upper Extremity Function in Patients With MS
Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis
Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch)
Effects of Dalfampridine on Cognition in Multiple Sclerosis
A New Medicine to Treat Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis
Dalfampridine and Gait in Spinocerebellar Ataxias
Short and Long Term Treatment With 4-AP in Ambulatory SMA Patients
Combination Therapy With Dalfampridine and Locomotor Training for Chronic, Motor Incomplete Spinal Cord Injury
4-Aminopyridine in Episodic Ataxia Type 2
A Randomized Trial to Evaluate Ampyra for Gait Impairment in Parkinson's Disease
Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis
An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra (BIIB041) When Used In Routine Medical Practice
Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch)
Dalfampridine for Imbalance in Multiple Sclerosis
Ampyra for Optic Neuritis in Multiple Sclerosis
Open Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine-Sustained Release (SR) in Canadian Participants With Multiple Sclerosis Who Participated in Acorda Extension Trials.